Health
MEPs supportive of draft Biotech report, but divisions over incentives remain
The European Parliament's first debate on its draft Biotech Act report showed broad political support for strengthening Europe's biotechnology sector, while exposing disagreements over how best to boost innovation, streamline clinical trials and incentivize investment.
Presenting their joint report, co-rapporteurs Wouter Beke MEP (EPP, Belgium) from the Industry, Research and Energy (ITRE) committee and Vytenis Andriukaitis MEP (S&D, Lithuania) from the Public Health (SANT) committee argued the legislation should position Europe as a global biotechnology leader by linking competitiveness with better patient access.
Beke warned that Europe is steadily losing ground to the United States and China in venture capital, clinical trials, manufacturing and commercialization, arguing that biotechnology has become "deeply geopolitical"....

Share this article:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
-
Science3 days agoEuropean Inventor Award 2026 winners announced: Honouring the innovators shaping tomorrow
-
Venezuela4 days agoEU delivers emergency aid and organises a humanitarian flight in response to earthquakes in Venezuela
-
Armenia4 days agoPresident von der Leyen travels to Azerbaijan and Armenia
-
Iraq4 days agoRegion Trade Bank strengthens international governance as Iraq's banking sector deepens global engagement
